Next article Search Articles Instructions for authors  Access Statistics | Citation Manager  
REVIEW ARTICLE  

 Article Access Statistics
    Viewed2672    
    Printed65    
    Emailed0    
    PDF Downloaded325    
    Comments [Add]    
    Cited by others 3    

Recommend this journal


Click on image for details.

 Antifibrinolytics and cardiac surgery: The past, the present, and the future

Naresh K Aggarwal, Arun Subramanian
Department of Cardiac Anesthesia, Manipal Hospitals, New Delhi, India

Correspondence Address:
Arun Subramanian
Department of Cardiac Anesthesia, Manipal Hospitals, Sector-6, Dwarka, New Delhi - 110 075
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/aca.ACA_205_18

Rights and Permissions

Year : 2020  |  Volume : 23  |  Issue : 2  |  Page : 193-199

 
SEARCH
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles

  Article in PDF (524 KB)
Email article
Print Article
Add to My List
Cardiac surgery is usually associated with significant blood loss, which often necessitates blood transfusion. In order to decrease the risks associated with the latter, pharmacological as well as nonpharmacological strategies have been used to reduce blood loss. Among the pharmacological approaches, antifibrinolytic drugs are the mainstay. Aprotinin, which was the first ubiquitously used drug, fell into disrepute only to re-emerge after much debate. The decline of aprotinin paved the way for the lysine analogs. However, we must be aware with the side effects of these drugs as well as the dose modification required in special situations. Nonsaccharide glycosaminoglycans have been under investigation to overcome the drawbacks of the lysine analogs. It remains to be seen whether these drugs can replace the traditional antifibrinolytics.






[FULL TEXT] [PDF]*
 

 

  Sitemap | Feedback | Disclaimer | Privacy Notice | What's New  
  © Annals of Cardiac Anaesthesia | Published by Wolters Kluwer - Medknow
 Online since 5th January, 2008

 

 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 
 
 Reader Comments
 Email Alert *
  *
 * Requires registration (Free)
 
 REVIEW ARTICLE
 



Naresh K Aggarwal, Arun Subramanian
Department of Cardiac Anesthesia, Manipal Hospitals, New Delhi, India

Correspondence Address:
Arun Subramanian
Department of Cardiac Anesthesia, Manipal Hospitals, Sector-6, Dwarka, New Delhi - 110 075
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/aca.ACA_205_18

Rights and Permissions

Cardiac surgery is usually associated with significant blood loss, which often necessitates blood transfusion. In order to decrease the risks associated with the latter, pharmacological as well as nonpharmacological strategies have been used to reduce blood loss. Among the pharmacological approaches, antifibrinolytic drugs are the mainstay. Aprotinin, which was the first ubiquitously used drug, fell into disrepute only to re-emerge after much debate. The decline of aprotinin paved the way for the lysine analogs. However, we must be aware with the side effects of these drugs as well as the dose modification required in special situations. Nonsaccharide glycosaminoglycans have been under investigation to overcome the drawbacks of the lysine analogs. It remains to be seen whether these drugs can replace the traditional antifibrinolytics.






[FULL TEXT] [PDF]*


        
Print this article     Email this article  

  Sitemap | Feedback | Disclaimer | Privacy Notice | What's New  
  © Annals of Cardiac Anaesthesia | Published by Wolters Kluwer - Medknow
 Online since 5th January, 2008